The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson’s disease Feb 20, 2026
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease Mar 19, 2024
The c-Abl inhibitor Risvodetinib (ABLi-148009) suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s disease Jan 18, 2023
Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson’s disease Aug 3, 2022
Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease Nov 1, 2020
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s disease Sep 1, 2020
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease Sep 1, 2019
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease Aug 21, 2019
Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration Jun 27, 2016